Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

A pharmacologically based multiscale mathematical model of angiogenesis and its use in investigating the efficacy of a new cancer treatment strategy.

Billy F, Ribba B, Saut O, Morre-Trouilhet H, Colin T, Bresch D, Boissel JP, Grenier E, Flandrois JP.

J Theor Biol. 2009 Oct 21;260(4):545-62. doi: 10.1016/j.jtbi.2009.06.026. Epub 2009 Jul 15.

PMID:
19615383
2.

Angiogenesis--a new target for future therapy.

Pandya NM, Dhalla NS, Santani DD.

Vascul Pharmacol. 2006 May;44(5):265-74. Epub 2006 Mar 20. Review.

PMID:
16545987
3.

Inhibition of tumor angiogenesis by angiostatin: from recombinant protein to gene therapy.

Dell'Eva R, Pfeffer U, Indraccolo S, Albini A, Noonan D.

Endothelium. 2002;9(1):3-10. Review.

PMID:
12901356
4.

Anti-angiogenic activity of human endostatin is HIF-1-independent in vitro and sensitive to timing of treatment in a human saphenous vein assay.

Macpherson GR, Ng SS, Forbes SL, Melillo G, Karpova T, McNally J, Conrads TP, Veenstra TD, Martinez A, Cuttitta F, Price DK, Figg WD.

Mol Cancer Ther. 2003 Sep;2(9):845-54.

5.
6.

Anti-angiogenic gene therapy of cancer: current status and future prospects.

Persano L, Crescenzi M, Indraccolo S.

Mol Aspects Med. 2007 Feb;28(1):87-114. Epub 2007 Jan 11. Review.

PMID:
17306361
7.

Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy.

Shinkaruk S, Bayle M, Laïn G, Déléris G.

Curr Med Chem Anticancer Agents. 2003 Mar;3(2):95-117. Review.

PMID:
12678905
8.

Development of new drugs in angiogenesis.

Ziche M, Donnini S, Morbidelli L.

Curr Drug Targets. 2004 Jul;5(5):485-93. Review.

PMID:
15216914
9.

Endostatin-cytosine deaminase fusion protein suppresses tumor growth by targeting neovascular endothelial cells.

Ou-Yang F, Lan KL, Chen CT, Liu JC, Weng CL, Chou CK, Xie X, Hung JY, Wei Y, Hortobagyi GN, Hung MC.

Cancer Res. 2006 Jan 1;66(1):378-84.

10.

Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy.

Abdollahi A, Folkman J.

Drug Resist Updat. 2010 Feb-Apr;13(1-2):16-28. doi: 10.1016/j.drup.2009.12.001. Epub 2010 Jan 12. Review.

PMID:
20061178
11.

Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors.

Fernando NT, Koch M, Rothrock C, Gollogly LK, D'Amore PA, Ryeom S, Yoon SS.

Clin Cancer Res. 2008 Mar 1;14(5):1529-39. doi: 10.1158/1078-0432.CCR-07-4126.

12.

Pathophysiological mechanisms of angiogenesis.

Walsh DA.

Adv Clin Chem. 2007;44:187-221. Review.

PMID:
17682343
13.

Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.

Shojaei F, Ferrara N.

Drug Resist Updat. 2008 Dec;11(6):219-30. doi: 10.1016/j.drup.2008.09.001. Epub 2008 Oct 23. Review.

PMID:
18948057
14.

Managing tumor angiogenesis: lessons from VEGF-resistant tumors and wounds.

Cuevas I, Boudreau N.

Adv Cancer Res. 2009;103:25-42. doi: 10.1016/S0065-230X(09)03002-4. Review.

PMID:
19854351
15.

Optimizing drug delivery for enhancing therapeutic efficacy of recombinant human endostatin in cancer treatment.

Xu F, Ma Q, Sha H.

Crit Rev Ther Drug Carrier Syst. 2007;24(5):445-92. Review.

PMID:
18197781
16.

Antiangiogenic therapy in malignant glioma: promise and challenge.

Sathornsumetee S, Rich JN.

Curr Pharm Des. 2007;13(35):3545-58. Review.

PMID:
18220791
17.

Adeno-associated virus-mediated antiangiogenic gene therapy with thrombospondin-1 type 1 repeats and endostatin.

Zhang X, Xu J, Lawler J, Terwilliger E, Parangi S.

Clin Cancer Res. 2007 Jul 1;13(13):3968-76.

18.

Evaluation of endostatin antiangiogenesis gene therapy in vitro and in vivo.

Jin X, Bookstein R, Wills K, Avanzini J, Tsai V, LaFace D, Terracina G, Shi B, Nielsen LL.

Cancer Gene Ther. 2001 Dec;8(12):982-9.

19.

Tumor endothelial cells are targets for selective therapies: in vitro and in vivo models to evaluate antiangiogenic strategies.

Dutour A, Rigaud M.

Anticancer Res. 2005 Nov-Dec;25(6B):3799-807. Review. Erratum in: Anticancer Res. 2006 Jan-Feb;26(1a):445.

20.

Antiangiogenic therapy for the treatment of pediatric solid malignancies.

Davidoff AM, Kandel JJ.

Semin Pediatr Surg. 2004 Feb;13(1):53-60. Review.

PMID:
14765371

Supplemental Content

Support Center